Total raised
—
Stage
Pre-Funding
Founded
2016
Headcount
6
HQ
Tel Aviv-Yafo
Sector
Health Tech & Life Sciences
About
GSKure is an IP-based company that owns innovative proprietary GSK-3 peptide inhibitor drug candidates.
The company's Kure products are based on a novel design of compounds that target a unique region at the GSK-3 protein surface termed the substrate binding site. The substrate-competitive inhibitors (SCIs) show improved selectivity and low toxicity compared to traditional ATP-competitive inhibitors.
GSKures novel SCI strategy for drug design offers significant advantages for clinical practice. Professor Hagit Eldar-Finkelman of Tel Aviv University conducted pioneering studies in developing GSK-3 inhibitors and their therapeutic use in treating human disease.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsBiotechnologyHealthcarePatients
Business model
B2B
Highlights
1 Patents
Tags
drug-discoveryneurosciencealzheimers-diseaseamyotrophic-lateral-sclerosis-alsdegenerative-diseasesdrug-designpatientspharma-companies